Skip to main content
Premium Trial:

Request an Annual Quote

GnuBio Licenses Nucleic Acid Analysis Methods

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – GnuBio announced today it obtained a worldwide license to microfluidics- and emulsion-based methods for nucleic acid analysis.

The technology, which was licensed from the laboratory of David Weitz, one of the founders of GnuBio, will be used by the startup firm to develop its DNA sequencer.

Weitz is a professor of physics and applied physics at Harvard University.

GnuBio is developing a scalable microfluidics-based sequencer where reactions take place in picoliter-sized drops. The goal is to sequence the human genome at 30x coverage at less than $100.

The platform would also have the capability to run diagnostic scale batches across a small candidate gene region at 100x coverage for less than $2 per sample, the company said in a statement

Terms of the deal were not disclosed.

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.